MX2023007741A - Formulaciones de upadacitinib de liberacion prolongada. - Google Patents

Formulaciones de upadacitinib de liberacion prolongada.

Info

Publication number
MX2023007741A
MX2023007741A MX2023007741A MX2023007741A MX2023007741A MX 2023007741 A MX2023007741 A MX 2023007741A MX 2023007741 A MX2023007741 A MX 2023007741A MX 2023007741 A MX2023007741 A MX 2023007741A MX 2023007741 A MX2023007741 A MX 2023007741A
Authority
MX
Mexico
Prior art keywords
upadacitinib
extended release
formulations
solid dosage
pharmaceutically acceptable
Prior art date
Application number
MX2023007741A
Other languages
English (en)
Inventor
Ye Huang
Yihong Qiu
Deliang Zhou
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2023007741A publication Critical patent/MX2023007741A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La descripción describe formas de dosificación sólidas de liberación prolongada que comprenden upadacitinib, o una sal farmacéuticamente aceptable del mismo, en donde la forma de dosificación sólida proporciona liberación de fármaco independiente del pH. En particular, la descripción describe formas de dosificación sólidas de liberación prolongada que comprenden upadacitinib, o una sal farmacéuticamente aceptable del mismo, al menos un polímero dependiente del pH y al menos un material de control de liberación.
MX2023007741A 2020-12-29 2021-12-29 Formulaciones de upadacitinib de liberacion prolongada. MX2023007741A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063131564P 2020-12-29 2020-12-29
PCT/US2021/065443 WO2022147073A1 (en) 2020-12-29 2021-12-29 Extended release upadacitinib formulations

Publications (1)

Publication Number Publication Date
MX2023007741A true MX2023007741A (es) 2023-09-15

Family

ID=82261098

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007741A MX2023007741A (es) 2020-12-29 2021-12-29 Formulaciones de upadacitinib de liberacion prolongada.

Country Status (8)

Country Link
US (3) US20240316040A1 (es)
EP (1) EP4271380A4 (es)
JP (1) JP2024501051A (es)
KR (1) KR20230127266A (es)
AU (1) AU2021411506A1 (es)
CA (1) CA3206839A1 (es)
MX (1) MX2023007741A (es)
WO (1) WO2022147073A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111909160B (zh) * 2019-05-09 2024-05-28 苏州鹏旭医药科技有限公司 一种乌帕替尼盐类化合物及其制备方法
CA3248817A1 (en) * 2022-01-20 2023-07-27 Renata Pharmaceutical (Ireland) Limited Extended-release pharmaceutical composition of Upadacitinib
EP4583877A1 (en) * 2022-09-09 2025-07-16 Intas Pharmaceuticals Ltd. Upadacitinib formulation
CN117357492A (zh) * 2023-10-31 2024-01-09 苏州天马医药集团天吉生物制药有限公司 一种乌帕替尼缓释片剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06003453A (es) * 2003-09-26 2006-08-31 Johnson & Johnson Barra de empuje oros para el suministro controlado de agentes activos.
US20090099154A1 (en) * 2005-06-29 2009-04-16 Panacea Biotec Ltd. Pharmaceutical Sustained Release Compositions and Processes Thereof
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
US20140271892A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Phenylephrine resinate particles having good auc
AU2018230500B2 (en) * 2017-03-09 2024-03-07 Abbvie Inc. Methods of treating Crohn's disease and ulcerative colitis
AU2018312349A1 (en) * 2017-08-01 2020-02-06 Theravance Biopharma R&D Ip, Llc Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
WO2020115212A1 (en) * 2018-12-05 2020-06-11 Lek Pharmaceuticals D.D. Crystalline phosphate salt of selective jak1 inhibitor upadacitinib

Also Published As

Publication number Publication date
WO2022147073A1 (en) 2022-07-07
JP2024501051A (ja) 2024-01-10
AU2021411506A9 (en) 2024-09-26
KR20230127266A (ko) 2023-08-31
US20240316040A1 (en) 2024-09-26
US20250161302A1 (en) 2025-05-22
CA3206839A1 (en) 2022-07-07
EP4271380A4 (en) 2025-01-22
US20260007661A1 (en) 2026-01-08
AU2021411506A1 (en) 2023-07-13
EP4271380A1 (en) 2023-11-08

Similar Documents

Publication Publication Date Title
MX2023007741A (es) Formulaciones de upadacitinib de liberacion prolongada.
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
EP4527467A3 (en) Pharmaceutical formulations
MX2015016112A (es) Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
PH12019501076A1 (en) Pharmaceutical formulations
GB202202470D0 (en) Bio-ink formulations, bio-printed corneal lenticule, and applications thereof
MY190855A (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
HK1254343A1 (zh) 药物制剂
MY209101A (en) Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof
SG10201902407PA (en) Injectable microparticles for hyper-localized release of therapeutic agents
MX2018011799A (es) Formas de dosificacion de liberacion prolongada disuasivas de abuso.
GB2581874B (en) Polyaryletherketone copolymer material, manufacture and use thereof
ZA202104704B (en) Pharmaceutical composition
MX2018008868A (es) Composiciones farmaceuticas que contienen glucomanano con liberacion extendida y propiedades disuasivas de abuso.
MY208261A (en) Oral pharmaceutical composition
PH12021552643A1 (en) Solid pharmaceutical composition comprising tlr7 agonist
EP4461361A3 (en) Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease
WO2018187698A3 (en) Combination therapies using caspase-1 dependent anticancer agents and pge2 antagonists
MX2020011321A (es) Profármacos de estrógeno y métodos de administración de profármacos de estrógeno.
MX2019001771A (es) Composición farmacéutica sólida que comprende el sofosbuvir amorfo.
MX2021002459A (es) Formas de dosificacion en capsula disuasorias del abuso de liberacion inmediata.
WO2015100370A3 (en) Sustained release depot formulations of therapeutic proteins, and uses thereof
WO2007016350A3 (en) Modified release tablet formulations with enhanced mechanical properties
MX2021002686A (es) Formulacion controlada de liberacion de farmacos.
IN2013MU03370A (es)